Janssen’s Xtandi Rival Up for MHLW Panel Review on Jan. 30; Enbrel Biosimilars Also on Agenda

January 17, 2019
Janssen Pharmaceutical’s prostate cancer drug apalutamide, also known as Erleada overseas, will come up for review by a key health ministry panel on January 30, with its green light expected to put the drug in line for official approval as...read more